Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-SID phase 3 trial of Panzyga for primary infection prophylaxis in CLL with secondary hypogammaglobulinemia
MOH_2021-09-23_010268Phase 3Completed
- Sponsor
- Octapharma
- Start
- Sep 2021
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of polyvalent human immunoglobulin in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Octapharma. Started Sep 2021; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2021-09-23_010268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-09-23_010268.